2022
Sick leave duration as a potential marker of functionality and disease severity in depression
VOLZ, H. P.; Eliška BARTEČKŮ; Lucie BARTOVA; J. BESSA; D. DE BERARDIS et al.Základní údaje
Originální název
Sick leave duration as a potential marker of functionality and disease severity in depression
Autoři
VOLZ, H. P.; Eliška BARTEČKŮ; Lucie BARTOVA; J. BESSA; D. DE BERARDIS; J. DRAGASEK; H. KOZHUHAROV; M. LADEA; J. LAZÁRY; M. ROCA; G. USOV; A. WICHNIAK; B. GODMAN a S. KASPER
Vydání
International Journal of Psychiatry in Clinical Practice, Oxon, TAYLOR & FRANCIS LTD, 2022, 1365-1501
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30215 Psychiatry
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.000
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/22:00126851
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
Absenteeism; depression; functionality; major depressive disorder; return to work; sick leave
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 16. 1. 2023 13:57, Mgr. Tereza Miškechová
Anotace
V originále
Objective: To discuss the impact of depression on work and how depression-related sick leave duration could be a potential indicator and outcome for measuring functionality in depression. Methods: Our review was based on a literature search and expert opinion that emerged during a virtual meeting of European psychiatrists that was convened to discuss this topic. Results: Current evidence demonstrates that depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions. A wide variety of pharmacological and non-pharmacological treatments and work-based interventions are effective in reducing depression-related sick leave duration and/or facilitating return to work. Recent real-world evidence showed that patients treated with antidepressant monotherapy appear to recover their working life faster than those receiving combination therapy. Although depression-related sick leave duration was found to correlate with severity of depressive symptoms, it cannot be used alone as a viable marker for disease severity. Conclusions: Given its multifactorial nature, depression-related sick leave duration is not on its own a viable outcome measure of depression severity but could be used as a secondary outcome alongside more formal severity measures and may also represent a useful measure of functionality in depression.